Critical shortage of new antibiotics in development against multidrug-resistant bacteria—Time to react is now☆
Keywords
Cited by (0)
- ☆
The views expressed in this article are the personal views of the authors. Those views may not be understood or quoted as being made on behalf, or reflecting, the position of ECDC, or of the EMA or one of its committees or working parties.
- 1
Ragnar Norrby (Swedish Institute for Infectious Disease Control, Solna, Sweden; ECDC-EMA Working Group), Mair Powell (MHRA, London, United Kingdom; ECDC-EMA Working Group), Dominique L. Monnet (ECDC, Stockholm, Sweden; ECDC-EMA Working Group), Bo Aronsson (EMA, London, United Kingdom; ECDC-EMA Working Group), Irja Lutsar (University of Tartu, Tartu, Estonia; ECDC-EMA Working Group), Ioan Bocsan (Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; ECDC-EMA Working Group), Helen Giamarellou (Hygeia Hospital, Athens, Greece; ECDC-EMA Working Group), Otto Cars (ReAct, Uppsala, University, Sweden; ECDC-EMA Working Group) and Inge C. Gyssens (Radboud University Medical Centre and CWZ Hospital Nijmegen, Nijmegen, The Netherlands; ECDC-EMA Working Group).